Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

Africa: First Malaria Drug for Newborns Gets Who Approval

The World Health Organization has approved the first malaria treatment designed for newborns and very young infants, marking a step forward in pediatric care. The medicine, artemether-lumefantrine, is tailored for babies 2-5 kg and meets international standards, according to WHO. This approval aims to reduce dosage errors and side effects previously seen when treating infants with drugs made for older children.

By Tertius News AI Desk 2 outlets · 2 articles Version 1 Coverage Apr 25–27, 2026 Published Aug 14

Lead

GENEVA — The World Health Organization has approved the first malaria treatment designed specifically for newborns and very young infants, a step that health officials say could improve outcomes for one of the most vulnerable groups affected by the disease. The medicine, artemether-lumefantrine, is the first antimalarial formulation developed for babies weighing between two and five kilograms, according to a WHO statement reported by multiple sources.

Coverage comparison

Coverage from AllAfrica emphasized the development as a way to enhance care for children most at risk, while the South China Morning Post framed the approval as a breakthrough, highlighting it as the first antimalarial formulation aimed at the youngest victims of the mosquito-borne disease. Both outlets quoted WHO Director-General Tedros Adhanom Ghebreyesus, with AllAfrica drawing attention to his optimism about new tools in the fight against malaria.

SCMP reported that the prequalification designation indicates the medicine meets international standards of quality, safety, and efficacy, as stated by WHO. AllAfrica's report included additional details, noting that the approval on April 24 allows governments and health agencies to purchase and distribute the treatment more widely, and mentioned the burden of the disease in Africa, where millions of babies are born each year in malaria-affected areas.

Key claims

Public health milestone: WHO's prequalification is a regulatory status indicating the medicine meets international standards for quality, safety, and efficacy, according to statements reported by SCMP and AllAfrica.
Addressing a gap: Previously, infants were treated with drugs intended for older children, raising the risk of dosing errors, side effects, and toxicity, as reported by SCMP.
Quotes from WHO chief: Ghebreyesus was quoted by both outlets: "For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities. But today, the story is changing. New vaccines, diagnostic tests, next-generation mosquito nets and effective medicines, including those adapted for the youngest, are helping to turn the tide."
Additional diagnostics: WHO has also approved three new rapid tests for malaria diagnosis, according to AllAfrica's report.

Perspectives

WHO Director-General Tedros Adhanom Ghebreyesus emphasized progress: "Ending malaria in our lifetime is no longer a dream - it is a real possibility, but only with sustained political and financial commitment."

Public health experts quoted in coverage highlighted the importance of this development, noting that it could significantly improve treatment outcomes for infants in malaria-endemic regions.

How each outlet told it

AllAfrica as of Apr 27, 2026, 3:15 PM UTC

Framing: Positive development in malaria treatment — Hopeful and optimistic

Facts Included:

WHO approved the first malaria treatment for newborns and very young infants
The medicine, artemether-lumefantrine, is designed for babies weighing between two and five kilograms
WHO's approval means the treatment meets international standards for safety and effectiveness
Around 30 million babies are born each year in areas affected by malaria in Africa
WHO has also approved three new rapid tests to improve malaria diagnosis

Read the source article →

South China Morning Post as of Apr 25, 2026, 12:16 AM UTC

Framing: Breakthrough in malaria treatment for newborns — Informative and objective

Facts Included:

WHO announced prequalification approval to a malaria treatment for newborns and infants
Artemether-lumefantrine is the first antimalarial formulation designed specifically for the youngest victims
The prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy

Read the source article →

What was claimed, and who backed it

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimThe World Health Organization (WHO) has approved the first malaria treatment made for newborns and very young infants.	ConfidenceHigh	StatusMulti-source quoted from AllAfrica as of Apr 27, 2026, 3:15 PM UTC the outlets behind this status were not recorded for this claim
ClaimThe medicine, artemether-lumefantrine, is designed for babies weighing between two and five kilograms.	ConfidenceHigh	StatusSingle-source via AllAfrica as of Apr 27, 2026, 3:15 PM UTC
ClaimWHO's approval means the treatment meets international standards for safety and effectiveness.	ConfidenceHigh	StatusMulti-source quoted from AllAfrica as of Apr 27, 2026, 3:15 PM UTC the outlets behind this status were not recorded for this claim
ClaimAround 30 million babies are born each year in areas affected by malaria in Africa.	ConfidenceHigh	StatusSingle-source via AllAfrica as of Apr 27, 2026, 3:15 PM UTC
ClaimWHO has also approved three new rapid tests to improve malaria diagnosis.	ConfidenceHigh	StatusSingle-source via AllAfrica as of Apr 27, 2026, 3:15 PM UTC
ClaimFor centuries, malaria has stolen children from their parents, and health, wealth and hope from communities, but today, the story is changing with new vaccines, diagnostic tests, next-generation mosquito nets and effective medicines.	ConfidenceHigh	StatusMulti-source quoted from South China Morning Post as of Apr 25, 2026, 12:16 AM UTC the outlets behind this status were not recorded for this claim
ClaimThe prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy.	ConfidenceHigh	StatusMulti-source quoted from South China Morning Post as of Apr 25, 2026, 12:16 AM UTC the outlets behind this status were not recorded for this claim

Transparency & Audit Trail

2 outlets · 2 articles consulted: AllAfrica, South China Morning Post 7 claims extracted Version 1 Written 2026-08-14